Concourse Financial Group Securities, Inc. Biotechnology

Concourse Financial Group Securities, Inc.

$0
Q2 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
PRTC Pure Tech Health PLC	$476M	$0 100.0% of portfolio	0	Q2 2025 New
PYXS Pyxis Oncology, Inc.	$45.3M	$0 100.0% of portfolio	0	Q2 2025 New
QSI Quantum Si Inc	$134M	$0 100.0% of portfolio	0	Q2 2025 New
RLYB Rallybio Corp	$17.4M	$0 100.0% of portfolio	0	Q2 2025 New
RANI Rani Therapeutics Holdings, Inc.	$12.5M	$0 100.0% of portfolio	0	Q2 2025 New
RXRX Recursion Pharmaceuticals, Inc.	$841M	$0 100.0% of portfolio	0	Q2 2025 New
REGN Regeneron Pharmaceuticals, Inc.	$61.9B	$0 100.0% of portfolio	0	Q2 2025 New
RGNX Regenxbio Inc.	$386M	$0 100.0% of portfolio	0	Q2 2025 New
RLAY Relay Therapeutics, Inc.	$440M	$0 100.0% of portfolio	0	Q2 2025 New
RLMD Relmada Therapeutics, Inc.	$32M	$0 100.0% of portfolio	0	Q2 2025 New
RNXT Renovo Rx, Inc.	$9.43M	$0 100.0% of portfolio	0	Q2 2025 New
RPTX Repare Therapeutics Inc.	$70M	$0 100.0% of portfolio	0	Q2 2025 New
REPL Replimune Group, Inc.	$266M	$0 100.0% of portfolio	0	Q2 2025 New
REVB Revelation Biosciences, Inc.	$63.5M	$0 100.0% of portfolio	0	Q2 2025 New
RVPH Reviva Pharmaceuticals Holdings, Inc.	$9.2M	$0 100.0% of portfolio	0	Q2 2025 New
RVMD Revolution Medicines, Inc.	$3.47B	$0 100.0% of portfolio	0	Q2 2025 New
RZLT Rezolute, Inc.	$276M	$0 100.0% of portfolio	0	Q2 2025 New
RYTM Rhythm Pharmaceuticals, Inc.	$5.81B	$0 100.0% of portfolio	0	Q2 2025 New
RCKT Rocket Pharmaceuticals, Inc.	$248M	$0 100.0% of portfolio	0	Q2 2025 New
ROIV Roivant Sciences Ltd.	$8.73B	$0 100.0% of portfolio	0	Q2 2025 New
RPRX Royalty Pharma PLC	$15.8B	$0 100.0% of portfolio	0	Q2 2025 New
RUBY Rubius Therapeutics, Inc.	$0	$0 100.0% of portfolio	0	Q2 2025 New
SABSW Sab Biotherapeutics Inc Wt Exp	$0	$0 100.0% of portfolio	0	Q2 2025 New
SAGE Sage Therapeutics, Inc.	$516M	$0 100.0% of portfolio	0	Q2 2025 New
SANA Sana Biotechnology, Inc.	$540M	$0 100.0% of portfolio	0	Q2 2025 New
SGMO Sangamo Therapeutics, Inc	$81.4M	$0 100.0% of portfolio	0	Q2 2025 New
SRPT Sarepta Therapeutics, Inc.	$1.59B	$0 100.0% of portfolio	0	Q2 2025 New
SVRA Savara Inc	$375M	$0 100.0% of portfolio	0	Q2 2025 New
SRRK Scholar Rock Holding Corp	$1.69B	$0 100.0% of portfolio	0	Q2 2025 New
SCPH Sc Pharmaceuticals Inc.	$151M	$0 100.0% of portfolio	0	Q2 2025 New
SEER Seer, Inc.	$120M	$0 100.0% of portfolio	0	Q2 2025 New
SLS Sellas Life Sciences Group, Inc.	$38.6M	$0 100.0% of portfolio	0	Q2 2025 New
SESN Sesen Bio, Inc.	$127M	$0 100.0% of portfolio	0	Q2 2025 New
STTK Shattuck Labs, Inc.	$41.5M	$0 100.0% of portfolio	0	Q2 2025 New
SLN Silence Therapeutics PLC	$173M	$0 100.0% of portfolio	0	Q2 2025 New
SILO Silo Pharma, Inc.	$2.01M	$0 100.0% of portfolio	0	Q2 2025 New
SBTX Silverback Therapeutics, Inc.	$0	$0 100.0% of portfolio	0	Q2 2025 New
SIOX Sio Gene Therapies Inc.	$0	$0 100.0% of portfolio	0	Q2 2025 New
SNGX Soligenix, Inc.	$134M	$0 100.0% of portfolio	0	Q2 2025 New
SRNE Sorrento Therapeutics, Inc.	$148M	$0 100.0% of portfolio	0	Q2 2025 New
SPRO Spero Therapeutics, Inc.	$72.6M	$0 100.0% of portfolio	0	Q2 2025 New
SWTX Spring Works Therapeutics, Inc.	$2.93B	$0 100.0% of portfolio	0	Q2 2025 New
STAB Statera Biopharma, Inc.	$0	$0 100.0% of portfolio	0	Q2 2025 New
STOK Stoke Therapeutics, Inc.	$779M	$0 100.0% of portfolio	0	Q2 2025 New
SMMT Summit Therapeutics Inc.	$4.84B	$0 100.0% of portfolio	0	Q2 2025 New
SRZNW Surrozen Inc Wt Exp 08/01/31 (	$0	$0 100.0% of portfolio	0	Q2 2025 New
STRO Sutro Biopharma, Inc.	$44.9M	$0 100.0% of portfolio	0	Q2 2025 New
SNDX Syndax Pharmaceuticals Inc	$924M	$0 100.0% of portfolio	0	Q2 2025 New
TNGX Tango Therapeutics, Inc.	$591M	$0 100.0% of portfolio	0	Q2 2025 New
TARS Tarsus Pharmaceuticals, Inc.	$1.56B	$0 100.0% of portfolio	0	Q2 2025 New

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.